IVIG in autoimmune disease - Potential next generation biologics
- PMID: 27019051
- DOI: 10.1016/j.autrev.2016.03.018
IVIG in autoimmune disease - Potential next generation biologics
Abstract
Polyclonal plasma-derived IgG is a mainstay therapeutic of immunodeficiency disorders as well as of various inflammatory autoimmune diseases. In immunodeficiency the primary function of IVIG/SCIG is to replace missing antibody specificities, consequently a diverse Fab-based repertoire is critical for efficacy. Attempts to capture the Ig repertoire and express it as a recombinant IVIG product are currently ongoing. Likewise correction of the defective genes by gene therapy has also been tried. However, both approaches are far from becoming mainstream treatments. In contrast, some of the most important effector mechanisms relevant in therapy of autoimmunity are based on the Fc-portion of IgG; they include scavenging of complement and blockade/modulation of IgG receptors (Fc gamma receptor [FcγR] or the neonatal Fc receptor [FcRn]). These effects might be achieved with appropriately formulated Fc-fragments instead of full-length IgG, as suggested by a pilot study with monomeric plasma-derived Fc in children with ITP and in Kawasaki disease in the 1990s. Since then it has been proposed that structured multimerization of Fc fragments might confer efficacy at much lower doses than with IVIG. Accordingly, various molecular strategies are currently being explored to achieve controlled Fc multimerization, e.g. by fusion of IgG1 Fc to the IgG2 hinge-region or to the IgM tail-piece. Safety considerations will be crucial in the evaluation of these new entities. In a different approach, mutant Fc fragments and monoclonal antibodies have been designed for blockade of the FcRn.
Keywords: Auto-antibodies; Auto-immune disease; IVIG; Multimerized Fc; Recombinant.
Copyright © 2016 Elsevier B.V. All rights reserved.
Similar articles
-
[Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders].Transfus Clin Biol. 2007 May;14(1):63-8. doi: 10.1016/j.tracli.2007.04.003. Epub 2007 May 10. Transfus Clin Biol. 2007. PMID: 17498995 Review. French.
-
[Mechanisms of immunoglobulins activity].Pol Merkur Lekarski. 2011 Jun;30(180):397-9. Pol Merkur Lekarski. 2011. PMID: 21751546 Polish.
-
Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases.Transfus Clin Biol. 2003 Jun;10(3):165-9. doi: 10.1016/s1246-7820(03)00035-1. Transfus Clin Biol. 2003. PMID: 12798851 Review.
-
Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Fc Receptor-Targeting Biologics.Pharmacology. 2020;105(11-12):618-629. doi: 10.1159/000508239. Epub 2020 Jun 22. Pharmacology. 2020. PMID: 32570239 Review.
-
Next-generation Fc receptor-targeting biologics for autoimmune diseases.Autoimmun Rev. 2019 Oct;18(10):102366. doi: 10.1016/j.autrev.2019.102366. Epub 2019 Aug 9. Autoimmun Rev. 2019. PMID: 31404703 Review.
Cited by
-
Bendamustine-induced immune hemolytic anemia: a case report and systematic review of the literature.Blood Adv. 2020 Apr 28;4(8):1756-1759. doi: 10.1182/bloodadvances.2020001726. Blood Adv. 2020. PMID: 32343794 Free PMC article.
-
rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs.J Immunol. 2018 Apr 15;200(8):2542-2553. doi: 10.4049/jimmunol.1701171. Epub 2018 Mar 12. J Immunol. 2018. PMID: 29531170 Free PMC article.
-
Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors.J Biol Chem. 2017 Aug 4;292(31):12994-13007. doi: 10.1074/jbc.M117.795047. Epub 2017 Jun 15. J Biol Chem. 2017. PMID: 28620050 Free PMC article.
-
Novel Therapies to Address Unmet Needs in ITP.Pharmaceuticals (Basel). 2022 Jun 23;15(7):779. doi: 10.3390/ph15070779. Pharmaceuticals (Basel). 2022. PMID: 35890078 Free PMC article. Review.
-
Multiple Variables at the Leukocyte Cell Surface Impact Fc γ Receptor-Dependent Mechanisms.Front Immunol. 2019 Feb 14;10:223. doi: 10.3389/fimmu.2019.00223. eCollection 2019. Front Immunol. 2019. PMID: 30837990 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources